|
This is a true statement because one had to be HLA - 2A positive to get the vaccine and this is a poorer prognositic indicator with the HLA-2A negative women standing as controls. So... it does reduce likelihood of recurrence against a better prognositic group (but how much so is this difference). They need to randomize differently including both groups. Secondly, the group was so small, when one additional recurrence occured prior to this meeting, the results became statistically irrevelant.
Dr. Winer commented later on the study saying it was interesting but the math was all wrong and how many boosters should be given after the intial set in order to maintain immunity?
More work needs to be done here for sure. Let's see if they have enough relevent data to get FDA approval for another clinical trial (or not)
__________________
Kind regards
Becky
Found lump via BSE
Diagnosed 8/04 at age 45
1.9cm tumor, ER+PR-, Her2 3+(rt side)
2 micromets to sentinel node
Stage 2A
left 3mm DCIS - low grade ER+PR+Her2 neg
lumpectomies 9/7/04
4DD AC followed by 4 DD taxol
Used Leukine instead of Neulasta
35 rads on right side only
4/05 started Tamoxifen
Started Herceptin 4 months after last Taxol due to
trial results and 2005 ASCO meeting & recommendations
Oophorectomy 8/05
Started Arimidex 9/05
Finished Herceptin (16 months) 9/06
Arimidex Only
Prolia every 6 months for osteopenia
NED 18 years!
Said Christopher Robin to Pooh: "You must remember this: You're braver than you believe and stronger than you seem and smarter than you think"
|
Linear Mode
